Silodosin Disease Interactions
There are 4 disease interactions with silodosin.
Silodosin (applies to silodosin) hepatic impairment
Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
The use of silodosin is contraindicated in patients with severe hepatic impairment. No dosage adjustment is needed in patients with mild or moderate hepatic impairment.
Silodosin (applies to silodosin) severe renal impairment
Major Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction
The use of silodosin is contraindicated in patients with severe renal impairment (CrCl < 30 mL/min). Caution and regular monitoring is recommended in patients with moderate renal impairment as the plasma concentrations can increase three times higher when compared with subjects with normal renal function. Dose should be reduced to 4 mg/day in patients with moderate renal impairment.
Alpha-1 blockers (applies to silodosin) hypotension
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Syncope, Dehydration
Peripheral alpha 1- adrenergic receptor blocking agents (aka alpha 1- blockers) cause vasodilation and can produce marked hypotension, especially orthostatic hypotension with syncope or other postural symptoms such as dizziness, lightheadedness, and palpitations. Orthostatic effects are most common during initiation of therapy and often occur within 90 minutes after the first dose. However, they can also occur following a dosage increase or resumption of therapy after an interruption of more than a few days. Agents with alpha 1a specificity, such as tamsulosin, act primarily on the prostate but are not devoid of hypotensive effects. Therapy with peripheral alpha-1 blockers should be administered cautiously in patients with or predisposed to hypotensive or syncopal episodes. Caution is also advised in patients who are dehydrated (e.g., due to severe or prolonged diarrhea or vomiting), since they may be more sensitive to the hypotensive effect of the drugs. Therapy should be initiated with the lowest dosage possible and titrated gradually based on patient response and tolerance in accordance with the individual product package labeling. During initiation or reinstitution of therapy and following an increase in dosage, patients should be advised not to rise abruptly from a sitting or recumbent position and to avoid situations where injury could result if syncope occur. Concomitant use of alcohol, extensive periods of standing, prolonged or intense exercise, and exposure to heat can also precipitate orthostatic hypotension and should be minimized. If dizziness, lightheadedness or palpitations occur, the patient should sit or lie down, and seek medical attention if symptoms are recurrent or bothersome.
Antiadrenergic agents (applies to silodosin) cataracts
Moderate Potential Hazard, Moderate plausibility.
Intraoperative Floppy Iris Syndrome has been observed during cataract surgery in some patients on or previously treated with antiadrenergic agents. If a patient is undergoing cataract surgery, the ophthalmologist should be prepared for possible modifications of the surgical technique (iris hooks, iris dilator rings). There does not appear to be a benefit in stopping antiadrenergic agents therapy prior to the cataracts surgery.
Silodosin drug interactions
There are 405 drug interactions with silodosin.
Silodosin alcohol/food interactions
There are 2 alcohol/food interactions with silodosin.
More about silodosin
- silodosin consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (128)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Drug class: alpha blockers
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.